Us Fda Approves J&j's Oral Psoriasis Pill

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Johnson & Johnson (NYSE:JNJ), Protagonist Therapeutics (NASDAQ:PTGX)

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older. FDA Approves Icotyde for Plaque Psoriasis in Adults and Teens Icotyde was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist Therapeutics, Inc. (NASDA…

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

'Potential Game Changer' for Psoriasis Gets Green Light From FDA

(MedPage Today) -- The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children 12 or older with moderate...

J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug, Icotyde, has the potential to top $5 billion in sales.

FDA approves Johnson & Johnson’s oral pill for psoriasis, company says

The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 years and older.

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.